LekoskopLekoskop
EN All changes
Medicine recalls and shortages › New approvals › 15 Jul 2025
MHRA approval

sebetralstat (Ekterly)

Published on 15 Jul 2025 · source: MHRA — Medicines and Healthcare products Regulatory Agency
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 15 July 2025, approved sebetralstat (Ekterly) for the treatment of hereditary angioedema (HAE) attacks in adults and adolescen…
MHRA announcement ↗ All events: sebetralstat (Ekterly)

What this means

The MHRA has announced the approval of a medicine or a new indication in the UK. Approval does not mean the product is already available on the NHS: NICE appraisal and commissioning may follow.

Summary

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 15 July 2025, approved sebetralstat (Ekterly) for the treatment of hereditary angioedema (HAE) attacks in adults and adolescents aged 12 years and older. 

Tracked from information published by the MHRA and the NHSBSA. This information is for guidance only and does not replace advice from your doctor or pharmacist.